Literature DB >> 2111289

Proteolysis of Clostridium perfringens type A enterotoxin during purification.

K B Park1, R G Labbé.   

Abstract

The small satellite bands of enterotoxin frequently seen in polyacrylamide gels following purification of Clostridium perfringens enterotoxin were found to be due to endogenous protease activity and were not present if phenylmethylsulfonyl fluoride (PMSF; 1 mM) and EDTA (10 mM) were used in the purification protocol. The use of PMSF was avoided by passing gel filtration-purified enterotoxin material through DEAE-Sephacel. This modified protocol resulted in an 11.4-fold purification of enterotoxin and a 26.8% yield. Contrary to previous reports (B. R. Dasgupta and M. W. Pariza, Infect. Immun. 38: 592-597, 1982), if PMSF and EDTA were included during purification, we were unable to detect the novel enterotoxin ET-1 produced by strain NCTC 10240. C. perfringens proteases cleaved homogeneous enterotoxin into two additional fragments, suggesting that ET-1 was a product of endogenous protease action during purification.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111289      PMCID: PMC258757          DOI: 10.1128/iai.58.6.1999-2001.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Preparative polyacrylamide gel electrophoresis purification of Clostridium perfringens enterotoxin.

Authors:  G L Enders; C L Duncan
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

2.  Artifacts following gold staining of Western-blotted membranes.

Authors:  K B Park; R G Labbé
Journal:  Anal Biochem       Date:  1989-07       Impact factor: 3.365

3.  Purification and biochemical properties of Clostridium perfringens type A enterotoxin.

Authors:  R L Stark; C L Duncan
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

4.  Purification and characteristics of the enterotoxin of Clostridium perfringens type A.

Authors:  A H Hauschild; R Hilsheimer
Journal:  Can J Microbiol       Date:  1971-11       Impact factor: 2.419

5.  Simplified method for purification of Clostridium perfringens type A enterotoxin.

Authors:  G Sakaguchi; T Uemura; H P Riemann
Journal:  Appl Microbiol       Date:  1973-11

6.  Trypsin activation of enterotoxin from Clostridium perfringens type A: fragmentation and some physicochemical properties.

Authors:  P E Granum; J R Whitaker; R Skjelkvåle
Journal:  Biochim Biophys Acta       Date:  1981-05-29

7.  Characterization of a parasporal inclusion body from sporulating, enterotoxin-positive Clostridium perfringens type A.

Authors:  A Löffler; R Labbé
Journal:  J Bacteriol       Date:  1986-02       Impact factor: 3.490

8.  Improved method for purification of enterotoxin from Clostridium perfringens type A.

Authors:  P E Granum; J R Whitaker
Journal:  Appl Environ Microbiol       Date:  1980-06       Impact factor: 4.792

9.  Purification of two Clostridium perfringens enterotoxin-like proteins and their effects on membrane permeability in primary cultures of adult rat hepatocytes.

Authors:  B R Dasgupta; M W Pariza
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

10.  Ileal loop fluid accumulation and production of diarrhea in rabbits by cell-free products of Clostridium perfringens.

Authors:  C L Duncan; D H Strong
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

View more
  3 in total

Review 1.  Bacterial extracellular zinc-containing metalloproteases.

Authors:  C C Häse; R A Finkelstein
Journal:  Microbiol Rev       Date:  1993-12

2.  Purification and characterization of an extracellular alpha-amylase from Clostridium perfringens type A.

Authors:  N J Shih; R G Labbé
Journal:  Appl Environ Microbiol       Date:  1995-05       Impact factor: 4.792

3.  Clostridium perfringens toxin genotypes in the feces of healthy North Americans.

Authors:  Robert J Carman; Sameera Sayeed; Jihong Li; Christopher W Genheimer; Megan F Hiltonsmith; Tracy D Wilkins; Bruce A McClane
Journal:  Anaerobe       Date:  2008-02-07       Impact factor: 3.331

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.